The U.S. Food and Drug Administration (FDA) approved Incyte’s Pemazyre (pemigatinib) for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement. It is the first and only FDA-approved drug for the indication.
Cholangiocarcinoma is a rare cancer of the bile duct that is classified based on anatomical origin. So, intrahepatic cholangiocarcinoma (iCCA) occurs in the bile duct inside the liver and extrahepatic cholangiocarcinoma occurs in the bile duct outside the liver. It is typically diagnosed late or at an advanced stage when the prognosis is poor.